7 Hills Pharma

7 Hills Pharma is a privately held, clinical-stage biotech advancing a novel platform of integrin-targeted small molecule agonists. Its lead asset, Alintegimod, is in a Phase 1b/2a trial to overcome anti-PD-1 resistance in solid tumors, while a second program, 7HP935, is in IND-enabling studies to improve stem cell therapies. The company has demonstrated strong non-dilutive funding prowess, securing over $34 million in grants from entities like the NIH and CPRIT to advance its pipeline. With a focused team and a promising mechanism of action to modulate the tumor microenvironment, 7 Hills is positioning itself as a potential key player in next-generation immunotherapy combinations.

Platform for developing first-in-class small molecule agonists of integrins (LFA-1 and VLA-4) designed to enhance immune cell trafficking and activation in the tumor microenvironment and improve stem cell engraftment.

In immuno-oncology, 7 Hills competes with numerous companies developing combination agents targeting TIGIT, LAG-3, and other costimulatory pathways. Its integrin agonist approach is mechanistically distinct. In stem cell transplantation, it faces competition from other companies developing small molecules, antibodies, and ex vivo cell engineering techniques to improve homing and engraftment.